Idris Bahce

4.6k total citations · 2 hit papers
103 papers, 2.5k citations indexed

About

Idris Bahce is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Idris Bahce has authored 103 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 64 papers in Pulmonary and Respiratory Medicine, 57 papers in Oncology and 35 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Idris Bahce's work include Lung Cancer Treatments and Mutations (48 papers), Lung Cancer Diagnosis and Treatment (31 papers) and Cancer Immunotherapy and Biomarkers (31 papers). Idris Bahce is often cited by papers focused on Lung Cancer Treatments and Mutations (48 papers), Lung Cancer Diagnosis and Treatment (31 papers) and Cancer Immunotherapy and Biomarkers (31 papers). Idris Bahce collaborates with scholars based in Netherlands, United States and United Kingdom. Idris Bahce's co-authors include Joachim G.J.V. Aerts, Paul Baas, Egbert F. Smit, Heike Peulen, Willemijn S.M.E. Theelen, Anna-Larissa N. Niemeijer, Adrianus J. de Langen, Vincent van der Noort, Kim Monkhorst and Jeltje F. de Vries and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Idris Bahce

94 papers receiving 2.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non–Small Cell Lung Cancer

2019 651 citations Vincent van der Noort, Idris Bahce et al. profile →
Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials

2020 353 citations Idris Bahce et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Idris Bahce Netherlands	24	1.6k	1.2k	558	475	472	103	2.5k
Jinming Yu China	19	1.2k 0.8×	671 0.5×	249 0.4×	456 1.0×	579 1.2×	66	2.3k
Thomas Gauler Germany	30	1.6k 1.0×	1.7k 1.4×	560 1.0×	481 1.0×	797 1.7×	152	3.1k
Adrianus J. de Langen Netherlands	24	1.1k 0.7×	1.5k 1.2×	1.0k 1.8×	270 0.6×	200 0.4×	49	2.5k
Saiama N. Waqar United States	29	1.7k 1.1×	1.9k 1.5×	292 0.5×	551 1.2×	654 1.4×	143	2.9k
Shyhmin Huang United States	23	1.5k 1.0×	1.0k 0.8×	380 0.7×	291 0.6×	1.1k 2.2×	39	2.4k
Willemijn S.M.E. Theelen Netherlands	16	3.0k 1.9×	3.3k 2.7×	235 0.4×	873 1.8×	998 2.1×	33	4.4k
Richard A. Messmann United States	21	1.2k 0.8×	1.4k 1.1×	1.3k 2.4×	362 0.8×	976 2.1×	49	3.2k
Anusha Kalbasi United States	18	1.5k 1.0×	695 0.6×	214 0.4×	238 0.5×	545 1.2×	62	2.6k
Yoichi Naito Japan	27	1.7k 1.1×	1.1k 0.9×	348 0.6×	428 0.9×	623 1.3×	150	2.7k
Magalie Hilton Switzerland	12	775 0.5×	1.0k 0.8×	297 0.5×	665 1.4×	692 1.5×	24	2.6k

Countries citing papers authored by Idris Bahce

Since Specialization

Citations

This map shows the geographic impact of Idris Bahce's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Idris Bahce with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Idris Bahce more than expected).

Fields of papers citing papers by Idris Bahce

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Idris Bahce. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Idris Bahce. The network helps show where Idris Bahce may publish in the future.

Co-authorship network of co-authors of Idris Bahce

This figure shows the co-authorship network connecting the top 25 collaborators of Idris Bahce. A scholar is included among the top collaborators of Idris Bahce based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Idris Bahce. Idris Bahce is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Huisman, Marc C., Sandeep S.V. Golla, D. Huglo, et al.. (2025). 89Zr-mAb uptake interpretation requires the use of tissue to plasma ratios corrected for antibody catabolism. EJNMMI Research. 15(1). 122–122.

Yaqub, Maqsood, Victor L. Thijssen, Adrianus J. de Langen, et al.. (2025). Physiologically Based Pharmacokinetic Model of Tyrosine Kinase Inhibitors to Predict Target Site Penetration, with PET‐Guided Verification. CPT Pharmacometrics & Systems Pharmacology. 14(5). 918–928. 1 indexed citations

Leest, Paul van der, Idris Bahce, D. Michiel Pegtel, et al.. (2025). Cell-Free DNA Based Next-Generation Sequencing Does Not Differentiate Between Oligoprogression and Systemic Progression in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors—An Explorative Study. International Journal of Molecular Sciences. 26(16). 8087–8087.

Schuit, Robert C., Chris Dickhoff, Jelena Levi, et al.. (2024). Pharmacokinetic analysis and simplified uptake measures for tumour lesion [18F]F-AraG PET imaging in patients with non-small cell lung cancer. European Journal of Nuclear Medicine and Molecular Imaging. 52(2). 719–729. 1 indexed citations

Bahce, Idris, Chris Dickhoff, Famke L. Schneiders, et al.. (2024). Single-arm trial of neoadjuvant ipilimumab plus nivolumab with chemoradiotherapy in patients with resectable and borderline resectable lung cancer: the INCREASE study. Journal for ImmunoTherapy of Cancer. 12(9). e009799–e009799. 5 indexed citations

Houda, Ilias, Chris Dickhoff, Carin A. Uyl‐de Groot, et al.. (2024). New systemic treatment paradigms in resectable non-small cell lung cancer and variations in patient access across Europe. The Lancet Regional Health - Europe. 38. 100840–100840. 18 indexed citations

Blaauwgeers, Hans, Birgit I. Lissenberg‐Witte, Andreas Schönau, et al.. (2024). Stereologic consequences of iatrogenic collapse: The morphology of adenocarcinoma in situ overlaps with invasive patterns. Proposal for a necessary modified classification of pulmonary adenocarcinomas. Lung Cancer. 197. 107987–107987.

Houda, Ilias, Chris Dickhoff, Carin A. Uyl‐de Groot, et al.. (2024). Challenges and controversies in resectable non-small cell lung cancer: a clinician’s perspective. The Lancet Regional Health - Europe. 38. 100841–100841. 17 indexed citations

Hashemi, Sayed M.S., Marc C. Huisman, Daniela E. Oprea‐Lager, et al.. (2024). First exploration of the on-treatment changes in tumor and organ uptake of a radiolabeled anti PD-L1 antibody during chemoradiotherapy in patients with non-small cell lung cancer using whole body PET. Journal for ImmunoTherapy of Cancer. 12(2). e007659–e007659. 3 indexed citations

10.

Houda, Ilias, Idris Bahce, Chris Dickhoff, et al.. (2023). OA06.03 An International EORTC Survey on Resectability of Stage III Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 18(11). S55–S56. 8 indexed citations

11.

Hashemi, Sayed M.S., Ilias Houda, Joris D. Veltman, et al.. (2023). Predictive Value of Combined Positive Score and Tumor Proportion Score for Immunotherapy Response in Advanced NSCLC. JTO Clinical and Research Reports. 4(9). 100532–100532. 24 indexed citations

12.

Ünal, Serhat, Agnita Stadhouder, David J. Heineman, et al.. (2023). Superior Sulcus Tumors Invading the Spine: Multimodal Treatment Outcomes From the Preimmunotherapy Era. JTO Clinical and Research Reports. 4(12). 100582–100582.

13.

Pol, Ymke van der, Norbert Moldován, Sandra A.W.M. Verkuijlen, et al.. (2022). The Effect of Preanalytical and Physiological Variables on Cell-Free DNA Fragmentation. Clinical Chemistry. 68(6). 803–813. 29 indexed citations

14.

Yaqub, Maqsood, Adriaan A. Lammertsma, Alex J. Poot, et al.. (2021). Identifying advanced stage NSCLC patients who benefit from afatinib therapy using 18F-afatinib PET/CT imaging. Lung Cancer. 155. 156–162. 11 indexed citations

15.

Hashemi, Sayed M.S., Marieke F. Fransen, Anna-Larissa N. Niemeijer, et al.. (2021). Surprising impact of stromal TIL’s on immunotherapy efficacy in a real-world lung cancer study. Lung Cancer. 153. 81–89. 49 indexed citations

16.

Dickhoff, Chris, Vincent van der Noort, Houke M. Klomp, et al.. (2020). Is pneumonectomy justifiable for patients with a locoregional recurrence or persistent disease after curative intent chemoradiotherapy for locally advanced non-small cell lung cancer?. Lung Cancer. 150. 209–215. 3 indexed citations

17.

Bahce, Idris, Sayed M.S. Hashemi, Chris Dickhoff, et al.. (2020). Factors influencing multi-disciplinary tumor board recommendations in stage III non-small cell lung cancer. Lung Cancer. 152. 149–156. 10 indexed citations

18.

Bosschieter, Judith, Sander Bach, Irene V. Bijnsdorp, et al.. (2018). A protocol for urine collection and storage prior to DNA methylation analysis. PLoS ONE. 13(8). e0200906–e0200906. 43 indexed citations

19.

Hansen, Søren B., Galith Abourbeh, Maqsood Yaqub, et al.. (2017). A multi species evaluation of the radiation dosimetry of [ 11 C]erlotinib, the radiolabeled analog of a clinically utilized tyrosine kinase inhibitor. Nuclear Medicine and Biology. 47. 56–61. 6 indexed citations

20.

Bahce, Idris, Egbert F. Smit, Mark Lubberink, et al.. (2012). Development of [11C]erlotinib Positron Emission Tomography for In Vivo Evaluation of EGF Receptor Mutational Status. Clinical Cancer Research. 19(1). 183–193. 92 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact